EGFR and non-small cell lung carcinoma: However, the next most optimal regimen for NSCLC patients without T790M mutations after failure of first and second generation EGFR‐TKIs or for patients who experienced failure with osimertinib has been poorly validated, and platinum combination chemotherapy is often selected.